NCT00747123View on ClinicalTrials.gov

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2008

Primary Completion Date

August 1, 2009

Study Completion Date

August 1, 2009

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

ACE-011

ACE-011 given by the subcutaneous route of administration monthly for 4 doses.

BIOLOGICAL

Placebo

Placebo given by the subcutaneous route of administration monthly for 4 doses.

Trial Locations (2)

Unknown

Investigative Site, Moscow

Investigative Site, Saint Petersburg

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY